Broadview Ventures Leads CHF 18M Seed Financing of HAYA Therapeutics

Choate represented Broadview Ventures as the lead investor in the CHF 18M seed financing of HAYA Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs). HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.

Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq, and Viva BioInnovator also participated in the funding round.